Lilly pens $202M deal for preclinical DNA delivery biotech Engage as M&A streak continues

There's no question Eli Lilly has been the most active biopharma dealmaker of recent months, but even the billions the pharma already spent on acquisitions hasn't exhausted its appetite. San Carlos-based Engage is developing non-viral DNA delivery systems that aim to overcome traditional limitations associated with the modality. Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Trending Biologics Clinical Development Ophthalmology Cell & Gene Therapy Drug Development Small Molecule Research & Development Fierce 50 Special Report Awards Gala Awards Outsourcing Awards Innovation Awards Resources Fierce Events…

Source: FierceBiotech